Italy Flu Diagnostic And Treatment Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type Of Flu (Type A, Type B), By Offering (Diagnostics (Rapid Influenza Diagnostic Test, Rapid Molecular Assay, Others), Therapeutics), By Age Group (0-14 Years, 15-64 Years, >=65 Years), And By End-User (Hospital Laboratory, Outpatient Clinic, Reference Laboratory) - Forecasts From 2022 To 2027

  • Published : Aug 2022
  • Report Code : KSI061613354
  • Pages : 75

The Italy flu diagnostic and treatment market is projected to grow at a CAGR of 12.51% throughout the forecast period to reach US$2,303.176 million in 2027, from US$1,009.356 million in 2020.

The flu diagnostic and treatment market in Italy is poised to surge at a notable CAGR, majorly on account of the rising investments in the healthcare sector coupled with the rising prevalence of influenza. The leading pharmaceutical sector of the country in the European Union is also one of the key factors which are bolstering the market growth throughout the forecast period. The increasing government expenditure in the biotechnology sector to uplift this segment is also anticipated to propel the growth opportunities for the market to have substantial growth during the next five years. Similarly, the growing investments in biotechnology R&D also show the potential for market growth in the coming years.

The Italian flu diagnostic and treatment market is expected to grow due to the flu season, seasonal flu outbreaks, established government healthcare, and others.

The high intensity of the flu prevalence in the country during the flu season is also anticipated to propel the growth opportunities for the market to surge during the forecast period. However, the outbreaks of flu are majorly seasonal throughout the country, which affects more than 9% of the population, especially the pediatric population. The well-established healthcare system of the country is also one of the key factors supporting the rapid growth of flu diagnostics and treatment in Italy in the coming years. The country follows a regionally based national health service, which is known as the Servizio Sanitario Nazionale (SSN). This service offers universal coverage to the citizens and residents of areas in which public healthcare is majorly free of charge. The medical services which are covered in this public system include surgeries, medications, tests, hospitalizations, doctor visits, and medical assistance, among others. All of these are contributing to the adoption of high-cost and advanced medical treatments and procedures, which are also projected to positively impact the market growth ahead.

Product Offerings

  • F. Hoffmann-La Roche Ltd. provides the Cobas® SARS-CoV- 2 and Influenza A & B tests. The company claims that the test kit can differentiate between COVID-19 and Flu. The test only takes 20 mins with minimum cross-contamination and risk of exposure during testing with the closed-system design.
  • Abbott’s ID NOWTM INFLUENZA A&B 2 molecular test is available in Italy, it delivers the results in 13 minutes or less using unique ID NOW platforms. Thus, making the test much faster and more accurate than other influenza tests.

COVID-19 Insights

Since the healthcare sector was overburdened with COVID-19 patients, the diagnostics and therapeutics for influenza cases declined to affect the market potential in 2020. Due to the COVID-19 pandemic in 2020 social distancing measures had been played, that played role in reducing influenza virus transmission. In Italy due to rigorous lockdowns and pandemic protocol, infectious diseases like influenza saw a decline in the number of cases. Influent, an Italian Influenza surveillance system reported in May 2022, that in all age groups flu-like syndromes were decreasing. Weekly monitoring of the epidemic curve of flu-like syndromes showed below the epidemic threshold level with incidents equal to 2.83 cases per thousand in a week assisted.  But after the restrictions were removed a surge in flu-like infection was observed in Italy, hence the need for the diagnostic and treatment market for flu surged resulting in the growth of the market during the forecast period.

Italy Flu Diagnostic and Treatment Market Scope:


Report Metric Details
 Market Size Value in 2020  US$1,009.356 million
 Market Size Value in 2027  US$2,303.176 million
 Growth Rate  CAGR of 12.51% from 2020 to 2027
 Base Year  2020
 Forecast Period  2022–2027
 Forecast Unit (Value)  USD Million
 Segments Covered  Type of Flu, Offering, Age Group, And End-User
 Companies Covered F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., 3M, SA Scientific, Meridian Bioscience™, Abott, bioMerieux SA
 Customization Scope  Free report customization with purchase



  • By Type of Flu
    • Type A
    • Type B
  • By Offering
    • Diagnostics
      • Rapid Influenza Diagnostic Test
      • Rapid Molecular Assay
      • Others
    • Therapeutics
  • By Age Group
    • 0-14 Years
    • 15-64 Years
    • >=65 Years
  • By End-User
    • Hospital Laboratory
    • Outpatient Clinic
    • Reference Laboratory

1. Introduction
1.1. Market Overview
1.2. COVID-19 Scenario
1.3. Market Definition
1.4. Market Segmentation

2. Research Methodology
2.1. Research Data
2.2. Assumptions

3. Executive Summary
3.1. Research Highlights

4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. Italy Flu Diagnostic and Treatment Market Analysis, By Type of Flu
5.1. Introduction
5.2. Type A
5.3. Type B

6. Italy Flu Diagnostic and Treatment Market Analysis, By Offering
6.1. Introduction
6.2. Diagnostics
6.2.1. Rapid Influenza Diagnostic Test
6.2.2. Rapid Molecular Assay
6.2.3. Others
6.3. Therapeutics

7. Italy Flu Diagnostic and Treatment Market Analysis, By Age Group
7.1. Introduction
7.2. 0-14 Years
7.3. 15-64 Years
7.4. >=65 Years
8. Italy Flu Diagnostic and Treatment Market Analysis, By End-User 
8.1. Introduction
8.2. Hospital Laboratory
8.3. Outpatient Clinic
8.4. Reference Laboratory

9. Competitive Environment and Analysis
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix

10. Company Profiles
10.1. F. Hoffmann-La Roche Ltd
10.2. Thermo Fisher Scientific Inc.
10.3. 3M
10.4. SA Scientific
10.5. Meridian Bioscience™
10.6. Abott
10.7. bioMerieux SA

F. Hoffmann-La Roche Ltd

Thermo Fisher Scientific Inc.


SA Scientific

Meridian Bioscience™


bioMerieux SA